FDA Says Eli Lilly Overstates Benefits Of Adcirca

Law360, New York (February 3, 2010, 5:47 PM EST) -- The U.S. Food and Drug Administration has warned Eli Lilly & Co. that marketing materials for its hypertension drug Adcirca overstate its effectiveness and omit information about risks associated with the prescription drug.

The FDA sent warning letters to Eli Lilly and United Therapeutics, which markets Adcirca in the U.S., asking them to immediately stop disseminating a Web page and a patient video about the drug, which is used to treat pulmonary arterial hypertension.

According to the FDA, the Web page discusses the most common side...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.